GovChime
Notice ID: ffa74c9b2d134f1bab1723b99440e712Combined Synopsis/SolicitationArchived

FY27-28 Adult Flu Vaccines

Archived on October 1, 2026. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
1:00 PM EDT
Posted
September 9, 2026
Notice type
Combined Synopsis/Solicitation
Set-aside
No Set aside used
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of Health and Human ServicesCENTERS FOR DISEASE CONTROL AND PREVENTION

Notice details

Office
CDC OFFICE OF ACQUISITION SERVICES
Place of performance
Atlanta, Georgia, 30329
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
75D30126R73517
Notice ID
ffa74c9b2d134f1bab1723b99440e712

Description

The Centers for Disease Control and Prevention (CDC) awards one or more Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts for the purchase of standard commercial adult vaccines.  The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial marketplace. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease.  The 317 program as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors.  The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage.  The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs, and current and former U.S. Territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act.  In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Cole Mullis

Secondary Contact

James Sprigler

Documents

Files (6)

  • A19 - 75D30126R73517 0001 - 1449 Solicitation Cover Page 2021 version.pdf

    699 KBAdded in Combined Synopsis/Solicitation version 3Posted
    Download
  • A19 75D30126R73517 0001 FY27-28 Adult Flu Sol..docx

    116 KBAdded in Combined Synopsis/Solicitation version 3Posted
    Download
  • A19 D-1 ADR.docx

    17 KBAdded in Combined Synopsis/Solicitation version 1Posted
    Download
  • A19 D-2 List of Products.docx

    17 KBAdded in Combined Synopsis/Solicitation version 1Posted
    Download
  • A19 D-3 AI Use Compliance and Risk Management Plan.docx

    26 KBAdded in Combined Synopsis/Solicitation version 1Posted
    Download
  • A19 D-4 Public Disclosure and Publication of Vaccine Pricing.docx

    17 KBAdded in Combined Synopsis/Solicitation version 1Posted
    Download

Lifecycle

  1. 1
    Version 1Combined Synopsis/SolicitationArchived

    FY27-28 Adult Flu Vaccines

    Notice 31d030bc5a2c43d6b4dfda797dc3d1ee on SAM.gov

  2. 3
    Version 3Combined Synopsis/SolicitationArchivedCurrent

    FY27-28 Adult Flu Vaccines

    Notice ffa74c9b2d134f1bab1723b99440e712 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Emergency Pharmacy Order of DigiFAB
-Sole Source / J&AOpen
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements. The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year. Justification: Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S. Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo. Requirements: SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101) SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260) Period of performance/Date of Delivery: Within 30 days of award, or mutually agreed upon. Place of Performance or Delivery: Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
-Pre-Solicitation11/11/2026
This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Item 0001: OXYGEN, USP, FILLED CYLINDER, SIZE D, 95GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5181 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0002: OXYGEN, USP, FILLED CYLINDER, SIZE H, 1650 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5199 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0003: NITROUS OXIDE, USP, FILLED CYLINDER, SIZE D, 250 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-130-1920 Shall be made in accordance with MIL-N-37996 DATED 24 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. ----------------------------------------------------- The Defense Logistics Agency Troop Support is seeking sources capable of providing the Medical Gas Cylinder in accordance with the Military Specifications listed above. NOTE: Only Type I-DOT 3AA STEEL Medical Gas Cylinders are acceptable. If your firm currently manufactures or distributes Type I-DOT 3AA STEEL Medical Gas Cylinders in accordance with the Military Specifications and changes attached, please provide information with respect to the following: Source and Part Number being supplied for each type of cylinder Place of manufacture for each type of cylinder Source for the Medical Gases Current unit sale price for each type of cylinder prefilled with the medical grade gas Estimated annual capacity for each type of cylinder/medical grade gas Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the ATNAA. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. Your response to this RFI may be submitted electronically via emailed to Jessica De La Hoz, Contracting Officer, Phone: 445-737-3623, Email: Jessica.DeLaHoz@dla.mil
-Market Research11/15/2026
Please see attached for the sources sought notice/market research survey and MPID.
-Market Research11/30/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
-Solicitation10/26/2026

Additional Details

Solicitation Number

75D30126R73517

Archive Date

Oct 1, 2026

Office Address

ATLANTA, GA, 30333